Key Takeaways
- 15.7% revenue growth, broad-based: Domestic grew 9.4% ahead of industry, international surged 22%, and emerging markets jumped 42% YoY, with all verticals contributing.
- Gross margin rebounded sharply QoQ: 61.8% vs 57.8% in Q4, driven by international product mix, though quarterly volatility is expected to persist.
- Pipeline bets are binary and back-half loaded: Amphotericin B approvals, Asparaginase filing, and wet AMD trial completion all converge in H2, making the second half the make-or-break window for FY26.
- The 5-year vision is now explicit and quantified: Management targets 300–400 bps margin expansion to 23–24% over 4–5 years, with one blockbuster launch planned for each of the next five years.
- What to watch next quarter: Whether the Amphotericin B ramp-up materializes as guided, the pace of Derma and Consumer Wellness prescription build, and any update on Asparaginase SEC review.
Domestic Business: Therapies, Portfolio Moves & New Bets
- Gynaec and Cardiac led: Both therapies grew much faster than industry, with the iron portfolio back on a double-digit growth trajectory and Orofer FCM's prescription side reviving strongly.
- Institution-side Orofer FCM still challenged: Competition at lower pricing continues to weigh on the institutional channel, though the majority of the business has now shifted to prescription-driven sales.
- Sanofi Cardiac portfolio integrated without cost bloat: The ~INR 200 crores annualized portfolio was absorbed into existing cardio-diabetes divisions with no new MRs added, keeping opex in check.
- Amaryl fills a strategic gap in metabolics: Sulfonylurea remains a first-line therapy, and the acquisition provides access to consulting physicians and diabetologists, strengthening the platform ahead of semaglutide's LOE opportunity.
- Derma and Consumer Wellness are patience bets: Both are in an 18–24 month gestation period, targeting ~1–2% additional domestic growth this year, with unique products driving early prescription traction.
- PCOS and menopause launches are early-stage concept-building: Launched last quarter, these are new therapy concepts being established in the market with good initial traction.
Satish Mehta: "With Amaryl coming to the fold, our position in the diabetics segment, metabolics will significantly strengthen and that will also help us when we go for semaglutide as and when we get to LOE."
International Business: The Growth Engine
- Emerging markets surged 42% YoY: Growth was driven by both ARV tender wins and non-ARV portfolio expansion, with new product approvals in target countries fueling the latter.
- ARV is lumpy by nature: Revenue from ARV depends on winning tenders, introducing uncertainty, while non-ARV growth is steadier and registration-driven.
- Canada delivered strong, sustainable growth: Market share gains and new launches drove performance, with the Mantra acquisition tracking ahead of expectations and product-level synergies now rolling out.
- Europe posted double-digit growth: A healthy pipeline supports the outlook, and Amphotericin B supply has begun actively in the UK with DCP approval received.
- Amphotericin B country-level approvals are a phased unlock: Each European country takes 3–5 months for national approval post-DCP, with revenue expected to start flowing from the end of this quarter.
- US exposure is minimal and tariff-insulated: Less than 3% of revenue comes from the US, making the company predominantly insulated from ongoing trade policy uncertainty.
Satish Mehta: "I want to highlight that your company is predominantly insulated from US market with our exposure to US being less than 3%."
Pipeline: The Binary Catalysts
- Liposomal Amphotericin B is the nearest-term blockbuster: Approvals are in place across major markets, two facilities with large lyophilization capacities are installed and ready, and full volume effect is expected within 12 months across geographies.
- Tenecteplase is building toward dominance: New registrations for MI indication are coming through, while doctor-driven uptake for stroke on a named-patient basis is pushing countries toward full registration, with management calling it a very dominant product in 18–24 months.
- r-Asparaginase dossier submitted, awaiting SEC: Trials were completed with an EU-approved reference product, and once Indian approval comes, the dossier can be filed across many countries.
- Bevacizumab trials designed for multi-market filing: Trials were conducted with emerging market dossier requirements in mind, positioning it for a broad launch.
- Wet AMD trial completes by September-end: The clinical trial is on track, after which the dossier will be compiled and submitted to CDSCO.
- Semaglutide filings are on schedule: Canada filing batches are being executed this month, targeting submission by fiscal year-end, while India efforts continue to be among the first wave of launches.
- GLP-1 incremental innovation in the works: Management is exploring tweaks to dosage systems and formulation for compliance improvement, with the synthetic route going off-patent in 2026.
Satish Mehta: "I take pride in telling everyone that as far as my company is concerned, it is in the forefront in launching new products and we're giving new products to the industry."
Margins & Capital Allocation
- Gross margin improved 400 bps QoQ to 61.8%: The swing was driven by product and business mix in international markets, though quarterly variations are expected to persist depending on mix across businesses.
- EBITDA margin expanded 80 bps YoY to 19.2%: Operating leverage and productivity gains supported the expansion, with ~100 bps of opex improvement expected for the full year vs last year.
- The opex improvement has three drivers: Better productivity from the Indian field force, scaling of the business, and better utilization of manufacturing facilities.
- Full-year margin expansion target is 150 bps: This breaks down into 100 bps from opex productivity and 50 bps from gross margin improvement.
- The 5-year margin ambition is 300–400 bps: Management aims to reach a 23–24% operating margin over 4–5 years, up from ~20% currently, driven by India productivity gains and an improving gross margin profile from the pipeline.
- Debt reduction is a near-term priority: Barring M&A, gross debt should approach close to zero by the end of this fiscal year, though the Manx and Zuventus acquisitions will temporarily add to the gross debt position.
- Capex is running at ~INR 350 crores annualized: Management will continue to evaluate M&A, strategic alliances, and in-licensing deals, with a focus hierarchy of India first, then emerging markets, Europe, and Canada.
Organization & Leadership
- New India President appointed: R.S. Vasan joins with 40 years of experience in India formulations, the last 15 at Sun Pharma, signaling a serious bet on domestic leadership depth.
- The 5-year vision is now the operating framework: Year one is about building a strong foundation through investments in new technologies, processes, and people to deliver highly profitable and above-average growth.
- One blockbuster launch per year is the explicit product strategy: Management claims crystal-clear clarity on one big product for each of the next five years, with filing batches and submissions already completed.
- Operational costs are largely inflation-linked: No meaningful increase beyond inflation and business-growth-driven spending is expected.
Satish Mehta: "This is the first year of our 5-year vision to take Emcure into the next orbit."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Domestic growth | Grow above industry | FY26 |
| Volume growth | 4–5% | FY26 |
| EBITDA margin expansion | 150 bps total (100 bps opex + 50 bps gross margin) | FY26 |
| Emerging markets growth | High teens to 20% | FY26 |
| Canada growth | Mid-teens | Sustainable, ongoing |
| Gross debt reduction | Approach close to zero, barring M&A | End of FY26 |
| Operating margin target | 23–24% (from ~20% now) | Over 4–5 years |
| Amphotericin B full volume effect | Max volumes across geographies | Next 12 months |
| Amphotericin B near-term revenue | Europe/UK/US approvals and supply | 4–6 months |
| Semaglutide Canada filing | Submission | End of FY26 |
| Wet AMD clinical trial completion | Trial complete, dossier to CDSCO | End of September 2025 |
| Asparaginase or wet AMD approval | At least one approval expected | FY26 |
| Derma and Consumer Wellness contribution | 1–2% additional domestic growth | FY26 |
| Tenecteplase dominance | Very dominant product | 18–24 months |
| r-Asparaginase and Bevacizumab ramp-up | Significant ramp-up across 4 products | 18–24 months |
Key Metrics
| Metric | Q1 FY26 |
|---|---|
| Revenue from operations | ₹2,101 cr, +15.7% YoY |
| Domestic revenue | ₹995 cr, +9.4% YoY |
| International revenue | ₹1,106 cr, +22% YoY |
| Emerging markets revenue | ₹360 cr, +42% YoY |
| Canada revenue | ₹342 cr, +16.4% YoY |
| Europe revenue | ₹403 cr, +12.8% YoY |
| Gross margin | 61.8%, vs 62.4% in Q1 FY25 and 57.8% in Q4 FY25 |
| EBITDA | ₹404 cr, +20.1% YoY |
| EBITDA margin | 19.2%, vs 18.5% in Q1 FY25 and 18.4% in Q4 FY25 |
| Profit after tax | ₹215 cr, +41% YoY, highest quarterly profit |
| Effective tax rate | 26% |
| Gross debt | ~₹700 cr |
| Cash and cash equivalents | ₹200 cr as of June 30, 2025, including investments |
| US exposure | Less than 3% of total business |
| India volume growth | ~4%, with price growth ~4% and new launches ~1-2% |
| Domestic growth ex-Orofer FCM | ~10.5%, Orofer FCM contributed ~1% drag |
| ARV share of emerging markets | ~50% |
| Sanofi diabetes portfolio | ~₹200 cr annualized, ~8 months contribution expected in FY26 |
| EBITDA margin expansion guidance for FY26 | 150 bps total, 100 bps from opex and 50 bps from gross margin improvement |
| Margin improvement target over 4-5 years | 300-400 bps expansion from current levels |
| Annual capex guidance | ~₹350 cr, split ~₹150 cr repair/maintenance and ~₹200 cr capacity/product-specific |
| Emerging markets growth guidance for FY26 | High teens to 20% |